

AUG - 1 2003

K 031993

## 510(k) SUMMARY OF SAFETY AND EFFECTIVENESS

### SYNERON MEDICAL Ltd. AURORA SR

This summary of safety and effectiveness information is being submitted in accordance with the requirements of the SMDA 1990 and 21 CFR 807.92.

**Submitter:** Syneron Medical Ltd., Appolo Bld.,  
Industrial Zone  
Yoqneam Illit, Israel  
Tel. +972.4.909-7424, Fax +972.4. 909-7417

**Name of the Device:** Aurora SR

**Predicate Devices:** This is a Special 510(k) for the Aurora SR that was cleared under K022266


**Device Description:** The Aurora SR is a device that is used for superficial benign vascular and pigmented lesion treatment. The Aurora SR treatment is based on a principle of *selective thermolysis*. According to this principle, parameters of optical and RF energy (spectrum, exposure duration and energy density) are chosen (and optimized) to selectively damage (destroy) vascular and pigmented lesions without damaging the surrounding tissues.

The Aurora SR is intended for use in dermatology for superficial benign vascular and pigmented lesion treatment.

The modifications to the Aurora SR do not affect the intended use or alter the fundamental scientific technology of the device. The only device modification an increase in the RF energy output. There are no labeling changes that affect the intended use of the device. The device modifications raise no new issues of safety or effectiveness.

24 June 2003

Date

  
Mr. Moshe Mizrahy  
CEO  
Syneron Medical Ltd.



Food and Drug Administration  
9200 Corporate Boulevard  
Rockville MD 20850

AUG - 1 2003

Dr. Amir Waldman  
Director, Regulatory Affairs  
Syneron Medical Ltd.  
Apollo Bld. Industrial Zone  
P.O Box 550  
Yoqneam Illit, 20692  
Israel

Re: K031993

Trade/Device Name: Aurora SR  
Regulation Number: 21 CFR 878.4810, 878.4400  
Regulation Name: Laser surgical instrument for use in general  
and plastic surgery and in dermatology,  
Electrosurgical cutting and coagulation device and accessories  
Regulatory Class: II  
Product Code: GEX, GEI  
Dated: June 24, 2003  
Received: July 2, 2003

Dear Dr. Waldman:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Page 2 - Dr. Amir Waldman

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (301) 594-4659. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <http://www.fda.gov/cdrh/dsma/dsmamain.html>

Sincerely yours,

*for*   
for Celia M. Witten, Ph.D., M.D.

Director  
Division of General, Restorative  
and Neurological Devices  
Office of Device Evaluation  
Center for Devices and Radiological Health

Enclosure

510(k) Number K 031993

Device Name Aurora SR

Indications For Use: (separate page)

The Aurora SR is indicated for **superficial benign vascular and pigmented lesion treatment.**

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use    
 (Per 21 CFR 801.109)

OR

Over The Counter Use

(Optional Format 1-2-96)

Miriam C. Provost  
(Division Sign-Off)  
Division of General, Restorative  
and Neurological Devices

510(k) Number K031993